Sensei Biotherapeutics (SNSE) Expected to Announce Quarterly Earnings on Friday

Sensei Biotherapeutics (NASDAQ:SNSE) is expected to be announcing its Q4 2025 results before the market opens on Friday, March 27th. Analysts expect the company to announce earnings of ($4.81) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, March 27, 2026 at 10:30 AM ET.

Sensei Biotherapeutics Trading Up 0.1%

SNSE opened at $30.55 on Friday. The company has a market cap of $38.49 million, a price-to-earnings ratio of -1.60 and a beta of -0.12. The stock has a fifty day simple moving average of $19.01 and a two-hundred day simple moving average of $12.80. Sensei Biotherapeutics has a 12-month low of $5.00 and a 12-month high of $36.76.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on SNSE. Wall Street Zen raised shares of Sensei Biotherapeutics to a “hold” rating in a research report on Saturday, December 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $55.00.

Institutional Investors Weigh In On Sensei Biotherapeutics

A hedge fund recently raised its stake in Sensei Biotherapeutics stock. Renaissance Technologies LLC raised its stake in Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 10.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 11,516 shares of the company’s stock after acquiring an additional 1,100 shares during the period. Renaissance Technologies LLC owned approximately 0.91% of Sensei Biotherapeutics worth $123,000 as of its most recent SEC filing. Institutional investors and hedge funds own 10.50% of the company’s stock.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.